Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T07:05:03.898Z Has data issue: false hasContentIssue false
  • English
  • Français

Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

Published online by Cambridge University Press:  01 August 2008

Hiroyuki Umegaki ,
Akio Itoh ,
Yusuke Suzuki  and
Toshitaka Nabeshima
Hiroyuki Umegaki*
Affiliation:
Department of Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan
Akio Itoh
Affiliation:
Department of Hospital Pharmacy, Nagoya University Graduate School of Medicine, Aichi, Japan
Yusuke Suzuki
Affiliation:
Department of Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan
Toshitaka Nabeshima
Affiliation:
Department of Chemical Pharmacology, Meijo University Graduate School of Pharmaceutical Sciences, Aichi, Japan
*
Correspondence should be addressed to: Hiroyuki Umegaki, Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. Phone: +81 52 744 2365; Fax: +81 52 744 2371. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Maintaining continuous pharmacological treatment of patients with dementia is often difficult. In the current study we surveyed the discontinuation of donepezil, a cholinesterase inhibitor, for the treatment of Alzheimer's disease in a Japanese geriatric outpatient clinic in a university hospital.

Methods: Using a retrospective chart review from 1 July 2003 to 30 June 2005, prescriptions of donepezil and the reasons for discontinuing the prescription in a university hospital were determined. The severity of dementia was evaluated by the clinical dementia rating (CDR).

Results: Out of 264 patients, 140 (53.1%) discontinued taking donepezil during the two-year observation period. The mean age of the continued group and the discontinued group did not differ significantly (79.5 ± 6.7, 79.8 ± 6.4, respectively). Kaplan-Meier analysis showed that the patients with more severe cognitive impairment (CDR score = 3) discontinued donepezil earlier and more frequently. The reasons for discontinuation were a change in the doctors treating the patients (n = 71), ineffectiveness (n = 16), gastrointestinal side-effects (n = 11), and others (n = 41). In patients with CDR = 1 or 2, changes of doctors were the most frequent reason for discontinuation. However, in patients with CDR = 3, ineffectiveness of the medication was the major reason for discontinuation.

Conclusion: Donepezil was frequently discontinued, and the rate of discontinuation was higher in patients with advanced dementia.

Keywords

Alzheimer's diseasedonepezilcholinesterase inhibitorclinical dementia rating
Type
Research Article
Information
International Psychogeriatrics , Volume 20 , Issue 4 , August 2008 , pp. 800 - 806
Copyright
© International Psychogeriatric Association 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.Google Scholar
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Systematic Review, 25, CD005593.Google Scholar
Blennow, K., de Leon, M. J. and Zetterberg, H. (2006). Alzheimer's disease. Lancet, 368, 387–340.Google Scholar
Evans, M., Ellis, A., Watson, D. and Chowdhury, T. (2000). Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. International Journal of Geriatric Psychiatry, 15, 50–53.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Frankfort, S. V. et al. (2005). Discontinuation of rivastigmine in routine clinical practice. International Journal of Geriatric Psychiatry, 20, 1167–1171.Google Scholar
Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. and Martin, R. L. (1982). A new clinical scale for the staging of dementia. British Journal of Psychiatry, 140, 566–567.CrossRefGoogle ScholarPubMed
Mauskopf, J. A., Paramore, C., Lee, W. C. and Snyder, E.H. (2005). Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy, 11, 231–251.CrossRefGoogle ScholarPubMed
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412.CrossRefGoogle ScholarPubMed
Suh, D. C., Thomas, S. K., Valiyeva, E., Arcona, S. and Vo, L. (2005). Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs & Aging, 22, 695–670.CrossRefGoogle ScholarPubMed
Umegaki, H., Suzuki, Y, Kuzuya, M. and Iguchi, A. (2007). Attitudes of Japanese general practitioners towards referrals of patients with dementia. Nippon Ronen Igakkai Zasshi, 44, 102–106.CrossRefGoogle ScholarPubMed